Bionano (BNGO) Q2 FY26 earnings call

Bionano reported strong Q2 FY26 results, primarily driven by increased clinical adoption and utilization of its Optical Genome Mapping (OGM) platform, particularly in international markets. The company achieved its highest-ever gross margin and simplified its financial profile by fully retiring its convertible debt. While flow cell demand outpaces supply, Bionano remains focused on driving profitable growth with existing users and expanding OGM's clinical evidence base.